| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Spectral AI, Inc.$1.82
+0.01 (+0.55%)
Market Cap
85.29 M
EPS
-0.53
P/E Ratio
-
Value Trade
1.42 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.99 M
R&D Expenses
2.00 M
Operating CF
-3.73 M
Total Assets
17.73 M
Total Liabilities
26.54 M
Equity
-8.81 M
D/E Ratio
12,345
27.62 %
Week
45.65 %
1 Month
82.31 %
3 Month
94.2 %
6 Month
-72.14 %
5 Year
-72.26 %
All Time
Cash Data
Cash Position
11.70 M
Monthly Burn
1.24 M
Runway
8.2 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
513.01 K
52 Week Range
1.18 - 3.21
% held by Insiders
15.64 %
% held by Institutions
7.58 %
Enterprise Value
83.57 M
Total Shares
31.84 M
Short %
8.77 %
Float Shares
24.67 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDAI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Spectral AI, Inc. (MDAI) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MDAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDAI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MDAI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDAISpectral AI Joins the American Board of Wound Management Foundation in Celebrating Wound Healing Awareness Month
Spectral AI, Inc. is partnering with the American Board of Wound Management Foundation to celebrate the 10th Annual Wound Healing Awareness Month. The company highlights its AI-driven DeepView System, which aids in diagnosing burn wounds and improving treatment outcomes. This initiative underscores the importance of timely care for patients with complex wounds.
Read more →MDAISpectral AI to Participate in 2026 British Burn Association Annual Conference
Spectral AI, Inc. will participate in the 2026 British Burn Association Annual Meeting, showcasing its FDA-approved DeepView System for burn wound assessment. The conference, held at Nottingham Trent University, will feature multiple presentations on the technology. The company anticipates its first commercial sales of the DeepView System by the end of 2026.
Read more →MDAISpectral AI Announces Voting Results of Annual Meeting of Stockholders
Spectral AI, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all proposals were approved. The company received FDA clearance for its DeepView System, allowing for commercial distribution in the U.S. Additionally, it secured $31.7 million in funding from BARDA to enhance the system's features. The company is set to initiate commercial sales by the end of 2026.
Read more →MDAISpectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication
Spectral AI has received FDA De Novo Classification for its DeepView System, which is designed for assessing burn wound healing potential. This clearance allows the company to begin commercial distribution in the U.S. The DeepView System utilizes AI and multispectral imaging to provide rapid diagnostic assessments, potentially enhancing patient outcomes in burn care.
Read more →MDAIReal-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities
MindBio Therapeutics is developing an AI-driven platform that uses voice analysis to detect intoxication in real-time. This innovative approach aims to address the limitations of traditional drug and alcohol testing methods, which are often invasive and slow. The company targets a substantial market in workplace safety and substance testing, estimated at $47 billion. By focusing on multi-substance detection, MindBio is positioning itself at the forefront of a growing field in noninvasive diagnostics.
Read more →MDAISpectral AI Announces 2026 First Quarter Financial Results
Spectral AI reported its financial results for Q1 2026, highlighting a net loss of $3.4 million. The company continues to develop its DeepView System under a $31.7 million BARDA contract. Despite a decline in R&D revenue, gross margins improved, and the company reaffirmed its annual revenue guidance of approximately $18.5 million.
Read more →MDAISpectral AI Wins Small Business Innovator Award at Inaugural Texas Innovation Conference
Spectral AI, Inc. received the Small Business Innovator Award at the Texas Innovation Conference for its DeepView System, an AI-driven diagnostic tool for assessing burn wound healing potential. The award acknowledges the company's efforts in transforming medical diagnostics and improving patient care. The DeepView System is designed to provide clinicians with immediate, data-driven assessments to enhance treatment decisions.
Read more →MDAISpectral AI Schedules 2026 First Quarter Financial Results and Conference Call
Spectral AI, Inc. will report its first quarter financial results for 2026 on May 12. A conference call will follow at 5:00 PM ET to discuss these results. The company is focused on advancing medical diagnostics in wound care through its DeepView System, which aims to enhance treatment decisions and patient outcomes.
Read more →MDAISpectral AI’s DeepView® System Showcased at 2026 American Burn Association Annual Meeting
Spectral AI showcased its DeepView System at the 2026 American Burn Association Annual Meeting, highlighting its potential in burn wound assessment. The AI-driven device provides immediate, data-driven evaluations to aid treatment decisions. Clinicians from the U.S. and U.K. presented various studies related to the system, emphasizing its innovative approach to improving patient care.
Read more →MDAISpectral AI Announces Annual Meeting of Stockholders
Spectral AI, Inc. has announced its 2026 Annual Meeting of Stockholders to be held on May 29, 2026. Only stockholders of record as of April 1, 2026, can vote at the meeting. The company is focused on advancing medical diagnostics in wound care with its DeepView System, which aims to improve treatment decisions.
Read more →MDAISpectral AI to Feature DeepView® System at 2026 American Burn Association Annual Meeting
Spectral AI, Inc. will showcase its DeepView® System at the American Burn Association Annual Meeting from April 14-17, 2026. The system offers predictive diagnostics for burn wounds, enabling clinicians to make informed treatment decisions. The company aims to revolutionize wound care management and has submitted a De Novo 510(k) application to the FDA for the system.
Read more →MDAISpectral AI Names David McGuire, CPA, as Chief Financial Officer
Spectral AI has appointed David McGuire as Chief Financial Officer, effective May 4, 2026. McGuire brings over 20 years of experience in finance and accounting, previously serving as Chief Accounting Officer at Solo Brands. His role is crucial as the company prepares for the commercialization of its DeepView System, aimed at improving wound care diagnostics.
Read more →MDAISpectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepView® System
Spectral AI has secured $31.7 million in funding from BARDA to enhance its DeepView System, an AI-driven technology for burn wound imaging. This funding is part of a larger contract aimed at improving medical diagnostics in burn care. The DeepView System is designed to assist healthcare professionals in making quicker, data-driven treatment decisions, particularly in emergency scenarios.
Read more →MDAISpectral AI Names Vincent S. Capone as Chief Executive Officer
Spectral AI has appointed Vincent S. Capone as its new Chief Executive Officer, effective February 9, 2026. Capone, previously the Chief Financial Officer and General Counsel, will lead the company as it transitions towards the commercialization of its AI-driven burn wound assessment device, the DeepView System. His leadership is expected to guide the company's strategic direction and enhance its innovative offerings in wound care.
Read more →MDAISpectral AI to Participate in National Burn Awareness Week 2026 February 1–7, 2026
Spectral AI, Inc. will participate in National Burn Awareness Week from February 1-7, 2026, collaborating with the American Burn Association to promote burn prevention strategies. The company will engage employees through various activities and highlight the importance of proactive safety measures in workplaces. Additionally, Spectral AI's DeepView System aims to enhance treatment decisions for burn injuries through predictive diagnostics.
Read more →MDAISpectral AI Announces 2025 Third Quarter Financial Results
Spectral AI, Inc. reported its Q3 2025 financial results, revealing a cash position of $10.5 million and a decline in research and development revenue by 54% to $3.8 million. The company is progressing towards its De Novo FDA submission and has adjusted its revenue guidance for FY 2025 down to $18.5 million. Despite the challenges, operational efficiency remains a focus.
Read more →MDAISpectral AI Schedules 2025 Third Quarter Financial Results and Conference Call
Spectral AI, Inc. announced its third quarter financial results will be reported on November 11, 2025. The company will host a conference call at 5:00 pm ET to discuss these results. Spectral AI focuses on AI-driven medical diagnostics, particularly in wound care, aiming to improve treatment outcomes with its DeepView System.
Read more →MDAISpectral AI raises $7.6 Million of Additional Growth Capital
Spectral AI, Inc. has announced a $7.6 million offering to fund the development of its DeepView System, aimed at enhancing medical diagnostics in wound care. The offering involves the issuance of 4 million shares at $1.90 each, with warrants for future purchase. The funding will help the company prepare for commercial readiness by 2026 while continuing its existing projects.
Read more →MDAISpectral AI Named to TIME’s List of World’s Top HealthTech Companies 2025
Spectral AI, Inc. has been named to TIME's World’s Top HealthTech Companies 2025 list, highlighting its innovative work in medical diagnostics for wound care. The recognition reflects the company's financial performance, reputation, and online engagement among thousands of HealthTech firms. Chairman J. Michael DiMaio emphasized the significance of this milestone for their DeepView technology, aimed at enhancing treatment decisions.
Read more →MDAIDeepView® System highlighted at the European Burns Association Congress
Spectral AI, Inc. showcased its DeepView System at the European Burns Association Congress, highlighting its role in advancing burn care. Presentations from various experts emphasized the technology's effectiveness and the positive reception it received. The company aims to enhance treatment decisions in wound care through its innovative AI-driven solutions.
Read more →MDAISpectral AI Announces Submission to FDA of its DeepView® System
Spectral AI has submitted a De Novo 510k marketing clearance application to the FDA for its DeepView System, which uses AI and multispectral imaging to assess burn healing potential. This submission marks a crucial step towards bringing the innovative device to market, aimed at enhancing clinical decision-making and patient outcomes in burn care settings.
Read more →MDAIDeepView® System highlighted at the annual British Burn Association conference
Spectral AI showcased its DeepView System at the British Burn Association conference, highlighting its potential to improve burn care. Key presentations revealed early positive experiences, including enhanced detection rates of non-healing wounds and improved clinical decision-making. The company's commitment to advancing burn treatment was emphasized by its leadership.
Read more →MDAISpectral AI Announces Appointment of Stanley Micek as Chief Operating Officer
Spectral AI has appointed Stanley Micek as Chief Operating Officer, transitioning from his role as Interim COO. Micek's leadership has been pivotal in overseeing teams working on the company's FDA submission and advancing their innovative DeepView® System for wound care. His experience in healthcare positions him well to lead the company's operational strategies.
Read more →Competitive Position
How MDAI ranks across every disease it competes inCompetitive Position is a premium feature
See how MDAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial